It’s a good sign for the stock market that the stock has begun to recover from the massive drop of around $13 per share last year, and that the pharmaceutical industry is back on track, even if it’s not yet as strong as it once was.

The company’s stock fell as much as 6% after reports surfaced that it had missed several milestones to deliver its EpiPen vaccine.

But it bounced back on Monday, closing at $5.85, up almost 7% on Tuesday morning.

It’s not the biggest gain in a year, but it’s a huge one for Merck, which has seen its stock plummet from $30.20 to around $20 per share since the election.

Merck’s stock has recovered from a near meltdown last year after it lost the battle against the deadly coronavirus.

The company was able to ramp up production of its Epitax EpiPens and other life-saving products.

But after a massive decline last year following the election, stocks in the pharmaceuticals sector suffered.

The latest drop is a big one, according to Andrew Gaffney, an analyst at Sterne Agee Research.

The pharmaceuticals industry has been in a downward spiral since the start of the year, according the National Association of Realtors.

The group said that the industry lost nearly $4.2 trillion in sales in the first quarter of 2018.

That’s up from a loss of $2.2 billion in the same quarter a year ago.

The industry also saw its revenue drop 2.9% in the last quarter of 2019.

“I think this is another big signal that the recovery is starting to pick up.

We’re seeing more and more companies showing signs of recovery and that’s encouraging to stock investors,” Gaffsey told Fox News.

Gaffney also pointed to the announcement by Merck on Monday that it is ending its contract with AstraZeneca, which it previously purchased, and it is moving toward purchasing another drugmaker, Pfizer.

“There are a lot of factors at play,” he said.

“It’s hard to say what will happen with the stock as it comes to the market at this point.

There’s also a lot going on at the state and federal level.

And that is a pretty large area where there’s some uncertainty.”

He added that the company is “still looking at what the next moves are going to be.”

“We’re in a very bullish market, with a lot more opportunities for growth,” Gaskin said.

While Merck’s shares have gained nearly 80% in 2017, the drugmaker has seen several big stock drops this year.

The first one occurred in May when it lost nearly 2% of its market value after its earnings report.

The next drop was a total loss in September when its shares fell by more than 4%.

The company said in the report that it expects to achieve an annual revenue of $4 billion by the end of 2019, which is down from an expected $8 billion in 2019.

The share price is down more than 20% since that time.

The recent drop in Merck comes as the drug companies are trying to ramp back up production and get on their feet after the election was called.

The drugmaker said it plans to resume the production of the EpiProne vaccine in early 2020 and that it will launch the Epipen, another life-defining device, in 2021.